Head-to-head evidence
Dapagliflozin vs janagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca
NCT00528372 · Phase 3 · completed
The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.
Next expected readout: October 2026 · NCT07033585 (registry estimate)
janagliflozin
Developed by Sihuan Pharmaceutical Holdings
NCT03811548 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled trial enrolled 442 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. Both the 25 mg and 50 mg doses of janagliflozin significantly outperformed placebo (p<0.001 for both), exceeding the trial's pre-specified superiority margin.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · janagliflozin's landscape